Eilandjes transplantatie. Eelco de Koning, LUMC 14 februari 2008
|
|
|
- Oswin Anthony
- 5 years ago
- Views:
Transcription
1 Eilandjes transplantatie Eelco de Koning, LUMC 14 februari 2008
2 Pancreas or islets? What tissue do we wish to transplant? Is there competition for donor pancreas? How does the islet isolation and transplantation procedure compare to pancreas transplantation? What are the complications? What is the outcome of islet transplantation for Glycemic control? Mortality? Kidney graft survival? Which patients?
3 Pancreas consists of only 1-2% 1 endocrine tissue (islets of Langerhans) 1 million islets
4 Competition for donor pancreas? Pancreas allocation (Eurotransplant( Eurotransplant) Donor pancreas Simultaneous kidney/pancreas transplantation (SPK) No Pancreas transplantation (PTA or PAK) No Islet transplantation
5 Where to transplant pancreatic islets?
6
7 Islet transplantation restores insulin pulsatility Meier JJ, Diabetes 2006
8 Persistent C-peptide C secretion despite loss of insulin independence after 5 years: Edmonton single center study Ryan E, Diabetes 2005
9 Multifactorial events leading to loss of Recurrent autoimmunity? Allograft rejection? islet mass Chronic islet toxicity by immunosuppressive drugs (most drugs diabetogenic) Early islet loss (IBMIR - instant blood-mediated inflammatory reaction) Robertson RP, N Engl J Med 350: , 2004
10 Islet transplantation and chronic diabetic complications Stabilizes diabetic retinopathy Improves cardiovascular function and vascular structure (Forina P et al., Diab Care 28: , 2005) Kidney-islet vs kidney alone Improves diastolic function Reduces progression in IMT Reduces BNP concentrations Stabilization of diabetic neuropathy in > 50% of patients
11 Complications of islet transplantation Procedure-related Bleeding liver (1%) Thrombosis portal vein (5 %) heparin (2-3 procedures usually necessary) Long-term Related to immunosuppressive agents (infections, cancer) Risk of immunisation
12 Complications?
13 Complications after pancreas or islet transplantation Lehrmann et al, Diabetologia 2006
14 Islet transplantation in the Netherlands Permission for islet isolation LUMC Isolation Permission for islet transplantation LUMC UMCG Transplantation
15 Islet transplantation outcome Major improvement in glucose fluctuations Strong reduction in hypoglycemic episodes and restoration of hypoglycemia awareness Improvement in quality of life even if not insulin-independent
16 Pancreas or islets? What is the goal of treatment? Reduction in mortality? Improvement in kidney graft survival? Improvement in glycemic control?
17 Cumulative survival after simultaneous pancreas-kidney (SPK) transplantation in type 1 diabetes and renal failure ( ) 1996) Leiden: SPK 75% Non-Leiden: SPK 37% Smets Y et al., Lancet 1999
18 Simultaneous-pancreas kidney transplantation in the Netherlands Number of SPK transplantations Leiden Groningen Graft survival (%) year 2 year 3 year 4 year
19 Type 1 diabetes with renal failure Simultaneous pancreas-kidney
20 Pancreas graft survival in PAK and PTA PAK yr: 57% PTA yr: 57% Sutherland DER and Gruessner AC, Transplant Proc 39: , 2007
21 A matter of experience? Graft survival (islets) Worldwide 700 Tx Edmonton 5 yr: 10% Graft survival (pancreas) Worldwide > Tx PAK yr: 57% PTA yr: 57% Sutherland DER and Gruessner AC, Transplant Proc 39: , 2007
22 Islet transplantation improves kidney graft survival in T1DM UAE median 11.9 mg/l Kidney-islet Kidneypancreas Kidney alone Fiorina P et al., Diabetes Care 28: , 2005
23 Continuous glucose monitoring after pancreas or islet transplantation Pancreas Islets Lehrmann et al, Diabetologia 2006
24 Type 1 diabetes with renal failure Type 1 diabetes with previous renal transplantation Simultaneous pancreas-kidney (SPK) transplantation Pancreas after kidney (PAK) transplantatiom Islets after kidney (IAK) transplantation (LUMC, UMCG)
25 Case 1: Type 1 diabetes and previous kidney transplantation: what to do? Male 53 yrs, T1DM since 31 yrs Admission for SPK, during operation too many adhesions for pancreas transplantation Case 2 Male 68 yrs, T1DM since 45 yrs, previous kidney transplantation Deterioration of vision due to DR Strict glycemic control, 4-5 per month severe hypoglycemia Case 3 Male 48 yrs, T1Dm since 26 yrs, previous SPK, pancreas graft failed Poor glycemic control, progressive DR Diffuse coronary abnormalities, PTCA, chest pain during low-impact exercise Case 4 Female 30 yrs, T1DM since 22 yrs Blind Severe hypoglycemia 2-3 x per week
26 Type 1 diabetes with renal failure Type 1 diabetes with previous renal transplantation Type 1 diabetes without renal failure Simultaneous pancreas-kidney (SPK) transplantation Pancreas after kidney (PAK) transplantatiom Islets after kidney (IAK) transplantation (LUMC, UMCG) Islets or pancreas? No referral?
27 Transplantation in patients with type 1 diabetes without renal insufficiency? A doctor s s dilemma Severe glycemic instability despite optimal insulin treatment (hypoglycemia unawareness and/or recurrent hypoglycemia) Severe autonomic neuropathy (postural hypotension, gastroparesis) Morbidity related to the pancreas transplantation Side-effects of immunosuppressive drugs
28 Islet transplantation the future? We only need the islets We do not want the procedure-related complications We can improve glycemic control and reduce microvascular complications But still suboptimal function in the long term But what does the patient want?
Islet and Pancreas Transplantation
Islet and Pancreas Transplantation Julie Wardle Specialist Nurse Coordinator Indication for Transplant Treatment option for a select groups of patients with type 1 diabetes Aged 18 years or over Recurrent
Clinical Policy: Pancreas Transplantation Reference Number: PA.CP.MP.102
Clinical Policy: Reference Number: PA.CP.MP.102 Effective Date: 01/18 Last Review Date: 03/17 Revision Log Coding Implications Description This policy describes the medical necessity requirements for pancreas
Allogeneic Pancreas Transplant
Protocol Allogeneic Pancreas Transplant (70302) Medical Benefit Effective Date: 07/01/14 Next Review Date: 05/15 Preauthorization Yes Review Dates: 09/09, 09/10, 09/11, 07/12, 05/13, 05/14 The following
Allogeneic Pancreas Transplant
Protocol Allogeneic Pancreas Transplant (70302) Medical Benefit Effective Date: 07/01/14 Next Review Date: 05/18 Preauthorization Yes Review Dates: 09/09, 09/10, 09/11, 07/12, 05/13, 05/14, 05/15, 05/16,
Islet Cell Transplantation The Oxford AHSN Diabetes Clinical Network Launch Event, February 2014
Islet Cell Transplantation The Oxford AHSN Diabetes Clinical Network Launch Event, February 2014 Stephen Gough Islet Transplant Service (Oxford) Islet v Pancreas Two different approaches Ideal Traetmanet
Pancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry
American Journal of Transplantation 2016; 16: 688 693 Wiley Periodicals Inc. Brief Communication Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons doi:
Pancreas Transplantation. Sonia Clarke-Swaby Recipient Kidney/pancreas Transplant Co-ordinator Guy s Hospital
Pancreas Transplantation Sonia Clarke-Swaby Recipient Kidney/pancreas Transplant Co-ordinator Guy s Hospital Introduction Selection criteria, New innovation Complications, Success rates, Life expectancy
Pancreas Transplantation: A Daring Concept 17 December 1966
Pancreas Transplantation Pancreas Transplantation: A Daring Concept 17 December 1966 Rutger J. Ploeg, MD PhD Abdominal & Transplant Surgery University Medical Centre Groningen The Netherlands Diabetes
Corporate Medical Policy
Corporate Medical Policy Pancreas Transplant File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pancreas_transplant 1/2000 5/2017 5/2018 8/2017 Description of Procedure or Service Transplantation
For more information about how to cite these materials visit
Author(s): Silas P. Norman, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
Pancreas and Pancreas-Kidney Transplantation By: Kay R. Brown, CLCP
Pancreas and Pancreas-Kidney Transplantation By: Kay R. Brown, CLCP Pancreas transplant recipients are usually under age 50. The majority of pancreas transplants are performed on diabetics, who are generally
Allogeneic Pancreas Transplant. Populations Interventions Comparators Outcomes Individuals: With insulin-dependent diabetes
Protocol Allogeneic Pancreas Transplant (70302) Medical Benefit Effective Date: 07/01/14 Next Review Date: 05/19 Preauthorization Yes Review Dates: 09/09, 09/10, 09/11, 07/12, 05/13, 05/14, 05/15, 05/16,
Chapter 4 Section Simultaneous Pancreas-Kidney (SPK), Pancreas-After-Kidney (PAK), And Pancreas-Transplant-Alone (PTA)
Surgery Chapter 4 Section 24.7 Simultaneous Pancreas-Kidney (SPK), Pancreas-After-Kidney (PAK), And Pancreas-Transplant-Alone Issue Date: February 5, 1996 Authority: 32 CFR 199.4(e)(5) 1.0 CPT 1 PROCEDURE
Chapter 4 Section 24.7
Surgery Chapter 4 Section 24.7 Simultaneous Pancreas-Kidney (SPK), Pancreas-After-Kidney (PAK), And Pancreas-Transplant-Alone (PTA), And Pancreatic Islet Cell Transplantation Issue Date: February 5, 1996
THE MEDICAL BENEFITS OF PANCREATIC TRANSPLANTATION
THE MEDICAL BENEFITS OF PANCREATIC TRANSPLANTATION Carlos E. Marroquin, M.D., F.A.C.S. Chief, Transplant and Hepatobiliary Surgery Department of Surgery Learning Objectives Describe historic events in
Allogeneic Pancreas Transplant. Description
Subject: Allogeneic Pancreas Transplant Page: 1 of 12 Last Review Status/Date: June 2015 Allogeneic Pancreas Transplant Description Transplantation of a normal pancreas is a treatment method for patients
NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE PANCREAS ADVISORY GROUP AUDIT OF STANDARD CRITERIA FOR LISTING SUMMARY
INTRODUCTION NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE PANCREAS ADVISORY GROUP AUDIT OF STANDARD CRITERIA FOR LISTING SUMMARY 1 Selection criteria for patients onto the national
FEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: January 15, 2019 Related Policies: 1.01.30 Artificial Pancreas Device Systems 7.03.12 Autologous Islet transplantation Allogeneic Pancreas Transplant Description
Kidney Transplantation
Kidney Tran nsplantation Historical per rspective and current practice Piyanut Poo otracool, M.D. Departmen nt of Surgery, Ramathibo odi Hospital, Mahidol University Kidney Transplantation DDKT Adult deceased
Original Policy Date
MP 7.03.10 Islet Transplantation Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy Index
Diabetic nephropathy and -cell replacement therapy
REVIEW Diabetic nephropathy and -cell replacement therapy J.W. de Fijter Department of Nephrology (C3-P22), Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, the Netherlands, tel.: +31 (0)71-526
Clinical impact of de-novo HLA antibodies in pancreas and islet transplantation
Clinical impact of de-novo HLA antibodies in pancreas and islet transplantation David Turner, PhD, FRCPath Lead for H&I Services, Scottish National Blood Transfusion Service Treatment of Type I DM Insulin
Vascular Remodelling in Pancreas Transplantation
Vascular Remodelling in Pancreas Transplantation Prof Steve White Consultant HPB/Transplant Surgeon The Freeman Hospital Newcastle President Elect EPITA European Pancreas Transplants Pancreas Transplants
PANCREAS TRANSPLANTATION WAS first described
0163-769X/04/$20.00/0 Endocrine Reviews 25(6):919 946 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/er.2002-0036 Pancreas Transplantation: Indications and Consequences JENNIFER
Allogeneic Pancreas Transplant
Allogeneic Pancreas Transplant Policy Number: 7.03.02 Last Review: 8/2014 Origination: 8/2001 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for allogeneic
Diabetes mellitus afflicts about 6% of. Review. Current Status of Pancreas and Islet Cell Transplantation
Review Current Status of Pancreas and Islet Cell Transplantation R. F. Saidi Assistant Professor of Surgery, Division of Organ Transplantation, Department of Surgery, University of Massachusetts Medical
Future Therapies in the Treatment of Diabetes: Islet Transplantation
Future Therapies in the Treatment of Diabetes: Islet Transplantation Michael R. Rickels, MD, MS Associate Professor of Medicine University of Pennsylvania Perelman School of Medicine Medical Director,
Transplantation in 2012:
Transplantation in 2012: Optimizing Outcomes through Seamless Communication Kidney, Pancreas and Islet Breakout Session Kidney Transplantation as a Treatment of Choice for ESRD Uday S. Nori, MD Assistant
CHAPTER 3 SECTION 1.6G SIMULTANEOUS PANCREAS-KIDNEY, PANCREAS-AFTER-KIDNEY, AND PANCREAS-TRANSPLANT-ALONE
TRICARE POLICY MANUAL 6010.47-M, MARCH 15, 2002 SURGERY AND RELATED SERVICES CHAPTER 3 SECTION 1.6G SIMULTANEOUS PANCREAS-KIDNEY, PANCREAS-AFTER-KIDNEY, AND PANCREAS-TRANSPLANT-ALONE ISSUE DATE: February
Islet Transplantation. Description
Subject: Islet Transplantation Page: 1 of 7 Last Review Status/Date: September 2015 Islet Transplantation Description Autologous islet transplantation, performed in conjunction with pancreatectomy, is
Topic: Pancreas Transplant Date of Origin: January Section: Transplant Last Reviewed Date: August 2013
Medical Policy Manual Topic: Pancreas Transplant Date of Origin: January 1996 Section: Transplant Last Reviewed Date: August 2013 Policy No: 6 Effective Date: November 1, 2013 IMPORTANT REMINDER Medical
The regenerative therapy of type 1 diabetes mellitus 21April 2017 Girne, Northern Cyprus 53rd Turkish National Diabetes Congress
The regenerative therapy of type 1 diabetes mellitus 21April 2017 Girne, Northern Cyprus 53rd Turkish National Diabetes Congress Thomas Linn Clinical Research Unit Centre of Internal Medicine Justus Liebig
Islet Cell Allo-Transplantation. Disclosure. Objectives
Islet Cell Allo-Transplantation Gregory P. Forlenza, MD MCR Assistant Professor Barbara Davis Center University of Colorado Denver Special thanks to Melena Bellin, MD at The University of Minnesota who
Simultaneous Pancreas Kidney Transplantation:
Simultaneous Pancreas Kidney Transplantation: What is the added advantage, and for whom? Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney
Allogeneic Pancreas Transplant
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
TRANSPLANTATION IN DIABETIC PATIENTS. A.Tarik Kizilisik, MD, MSc, FACS, FICS Director & Primary Transplant Surgeon Lutheran Transplant Center
TRANSPLANTATION IN DIABETIC PATIENTS A.Tarik Kizilisik, MD, MSc, FACS, FICS Director & Primary Transplant Surgeon Lutheran Transplant Center Diabetes is the pandemic of the new millennium 24 million diabetics
UEMS & EBS: DIVISION OF TRANSPLANT SURGERY
CURRICULUM AND SYLLABUS TRANSPLANTATION Module 1: Multi-organ retrieval Ability to evaluate donor suitability Ability to retrieve abdominal organs for transplantation Evaluation of donor/ organs suitability
Why is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
Stratégie de transplantation chez le patient diabétique de type 1. Transplantation strategy in Type 1 diabetic patient
Stratégie de transplantation chez le patient diabétique de type 1 Transplantation strategy in Type 1 diabetic patient Emmanuel Morelon Service de Transplantation, Néphrologie et Immunologie Clinique Hôpital
José Oberholzer, MD. Director Charles O. Strickler Transplant Center. Chief, Division of Transplantation
José Oberholzer, MD Director Charles O. Strickler Transplant Center Chief, Division of Transplantation Professor of Surgery and Biomedical Engineering DISCLOSURES No consulting for, no payments, no stocks
The state of affairs of allogenic islet transplantation. William Bennet MD, PhD Fellow Division of Transplant Surgery UCHSC
The state of affairs of allogenic islet transplantation William Bennet MD, PhD Fellow Division of Transplant Surgery UCHSC Global epidemiology of Diabetes Mellitus IDDM NIDDM 1997 3 700 000 120 300 000
The number of patients waiting on the pancreas transplant list fell by 7% during the year, to 252 at 31 March 2015
6 Pancreas Activity Pancreas Activity Key messages The number of patients waiting on the pancreas transplant list fell by 7% during the year, to 252 at 31 March 2015 The number of pancreas donors after
Original Policy Date
MP 7.03.03 Allogeneic Pancreas Transplant Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy
Records. Adult Kidney Pancreas Transplant Recipient Registration Worksheet. Recipient Information. Provider Information.
Records Adult Kidney Pancreas Transplant Recipient Registration Worksheet FORM APPROVED: O.M.B. NO. 0915 0157 Expiration Date: 07/31/2020 Note: These worksheets are provided to function as a guide to what
The number of patients waiting on the pancreas transplant list fell by 1% during the year, to 224 at 31 March 2017
6 Pancreas Activity Pancreas Activity Key messages The number of patients waiting on the pancreas transplant list fell by 1% during the year, to 224 at 31 March 2017 The number of pancreas donors after
HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2013 September 01.
Choices in kidney transplantation in type 1 diabetes: Are there skeletal benefits of the endocrine pancreas? Julia J. Scialla, MD, MHS Division of Nephrology and Hypertension, Department of Medicine, University
Islet Transplantation
Islet Transplantation Policy Number: Original Effective Date: MM.07.027 07/01/2014 Line(s) of Business: Current Effective Date: HMO; PPO 12/16/2016 Section: Transplants Place(s) of Service: Inpatient I.
POLICY GUIDELINES GENERAL CRITERIA
Medical Policy MP 7.03.02 BCBSA Ref. Policy: 7.03.02 Last Review: 08/30/2017 Effective Date: 08/30/2017 Section: Surgery End Date: 08/19/2018 Related Policies 1.01.30 Artificial Pancreas Device Systems
The Role of Kidney-Pancreas Transplantation in Diabetic Kidney Disease
Curr Diab Rep (2010) 10:385 391 DOI 10.1007/s11892-010-0136-0 The Role of Kidney-Pancreas Transplantation in Diabetic Kidney Disease Alexander C. Wiseman Published online: 27 July 2010 # The Author(s)
Allogeneic Pancreas Transplant
Allogeneic Pancreas Transplant Policy Number: Original Effective Date: MM.07.002 03/23/2001 Line(s) of Business: Current Effective Date: HMO; PPO 09/01/2013 Section: Transplants Place(s) of Service: Inpatient
SURGICAL CURES FOR DIABETES
SURGICAL CURES FOR DIABETES UCSF Diabetes Update March 12, 2009 Andrew M. Posselt, MD, PhD Transplant Surgery, UCSF Surgical Treatment Options Whole Organ Pancreas Transplant Type 1 and 2 Pancreatic Islet
Australia & New Zealand Pancreas. Transplant Registry Report
Australia & New Zealand Pancreas Transplant Registry Report 1984-2009 This report is a compilation of data provided by the three current Pancreas transplant units in Australia and New Zealand: Auckland
Allogeneic Pancreas Transplant
Allogeneic Pancreas Transplant Policy Number: 7.03.02 Last Review: 8/2018 Origination: 8/2001 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for allogeneic
Australia & New Zealand Pancreas. Transplant Registry Report Inquiries or comments should be directed to the secretariat at:
Australia & New Zealand Pancreas Transplant Registry Report 1984-2013 This report is a compilation of data provided by the four current Pancreas transplant units in Australia and New Zealand: Auckland
IMPORTANT REMINDER DESCRIPTION. Transplantation of a normal pancreas is a treatment method for patients with diabetes. MEDICAL POLICY CRITERIA
Medical Policy Manual Transplant, Policy No. 06 Pancreas Transplant Next Review: August 2018 Last Review: August 2017 Effective: October 1, 2017 IMPORTANT REMINDER Medical Policies are developed to provide
KIDNEY & PANCREAS TRANSPLANT OUTCOMES 2018
KIDNEY & PANCREAS TRANSPLANT OUTCOMES 201 Vanderbilt Transplant Center James George, kidney transplant patient A HISTORY OF EXCELLENCE anderbilt s transplant services have a long history of excellence.
Pancreas Transplantation From Living Donors: A Single Center Experience of 20 Cases
American Journal of Transplantation 2016; 16: 2413 2420 Wiley Periodicals Inc. Copyright 2016 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.13738
MEDICAL POLICY. POLICY NUMBER: CATEGORY: Transplants
MEDICAL POLICY SUBJECT: PANCREAS TRANSPLANT: (PANCREAS TRANSPLANT ALONE, PANCREAS AFTER KIDNEY TRANSPLANT, SIMULTANEOUS PANCREAS KIDNEY TRANSPLANT); ISLET CELL TRANSPLANT CATEGORY: Transplants EFFECTIVE
Manchester Royal Infirmary Renal & Pancreas Transplant Unit / 2012 Activity Annual Report
Manchester Royal Infirmary Renal & Pancreas Transplant Unit 211 / 212 Activity Annual Report Vicki Bowman Renal Transplant Audit & Data Manager Dr Susan Martin Consultant Clinical Scientist / Transplantation
THE BIOARTIFICIAL PANCREAS
THE BIOARTIFICIAL PANCREAS A CLINICAL CASE SCENARIO ANALYSIS TO ASSESS AND SUPPORT THE DEVELOPMENT OF A DEVICE TO IMPROVE TYPE 1 DIABETES CARE Master thesis Health Sciences TB Wissing student number: 0127353
HIHIM Clinical Cocepts for Managers 7/31/2009. Fernando Vega, MD 1
Fernando Vega, MD HIHIM 409 July 31, 2008 Hyperglycemia characterized by relative or absolute lack of insulin secretion Varying degrees of insulin resistance Often associated with symptoms: polyruia, polydipsia,
Beta-Cell Replacement by Transplantation in Diabetes Mellitus: When Pancreas, When Islets, and How To Allocate the Pancreas?
Trends David E.R. in Transplant. Sutherland 2010;4:99-107 and Dixon B. Kaufmann: Beta-Cell Replacement by Transplantation in Diabetes Mellitus Beta-Cell Replacement by Transplantation in Diabetes Mellitus:
Australia & New Zealand Pancreas. Transplant Registry Report
Australia & New Zealand Pancreas Transplant Registry Report 1984-2007 This report is a compilation of data provided by the five current Pancreas transplant units in Australia and New Zealand: Auckland
Current indications for pancreas or islet transplant
REVIEW ARTICLE doi: 10.1111/j.1463 1326.2004.00460.x Current indications for pancreas or islet transplant Edmond A. Ryan, 1 David Bigam 2 and A. M. James Shapiro 2 1 Department of Medicine, Clinical Islet
Diabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
GLUCOSE TESTING-BLOOD
648.83 ABNORMAL GLUCOSE TOLERANCE COMPLICATING PREGNANCY, CHILDBIRTH OR THE PUERPERIUM, ANTEPARTUM CONDITION OR 648.84 ABNORMAL GLUCOSE TOLERANCE COMPLICATING PREGNANCY, CHILDBIRTH OR THE PUERPERIUM, POSTPARTUM
Diabetes and Kidney Disease: Time to Act. Your Guide to Diabetes and Kidney Disease
Diabetes and Kidney Disease: Time to Act Your Guide to Diabetes and Kidney Disease Diabetes is fast becoming a world epidemic Diabetes is reaching epidemic proportions worldwide. Every year more people
Is Pancreas Transplantation Getting Old? Single-Center Experience in an Aging Society
165 Is Pancreas Transplantation Getting Old? Single-Center Experience in an Aging Society Richard Viebahn 1, Harald Klein 2, Bernhard Kraemer 3 and Peter Schenker 1 1 Department of Surgery, Knappschaftskrankenhaus,
Xenotransplantation: A Revolutionary Option for Diabetes Treatment
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2017, 9 [5]:201-206 [http://scholarsresearchlibrary.com/archive.html] ISSN 0975-5071 USA CODEN: DPLEB4
hypoglycaemia unawareness keystone 18 July 2014
hypoglycaemia unawareness keystone 18 July 2014 Hypoglycaemia unawareness: ( Impaired awareness of hypoglycaemia ) Philip Home Newcastle University Philip Home Duality of interest Manufacturers of glucose-lowering
TransplantUpdate. A Report From Baylor Regional Transplant Institute Volume 1 Number 4
TransplantUpdate A Report From Baylor Regional Transplant Institute Volume 1 Number 4 Alcoholic Liver Disease 2 Alcoholic liver disease is the second leading indication for liver transplantation in the
FIRST SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANT IN SINGAPORE
EMBARGOED TILL 18 OCTOBER, 2:30PM MEDIA RELEASE FIRST SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANT IN SINGAPORE The first simultaneous pancreas and kidney (SPK) transplant in Singapore was successfully
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
Microvascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
J Am Soc Nephrol 14: , 2003
J Am Soc Nephrol 14: 208 213, 2003 Kidney Allograft and Patient Survival in Type I Diabetic Recipients of Cadaveric Kidney Alone Versus Simultaneous Pancreas/Kidney Transplants: A Multivariate Analysis
Combining Complex Pathophysiologic Concepts: Diabetes Mellitus
Chapter 18 Combining Complex Pathophysiologic Concepts: Diabetes Mellitus KEY TERMS dawn phenomenon diabetes mellitus endocrine pancreas exocrine pancreas hyperglycemia hyperketonemia hypoglycemia insulin
H. Le Dinh, A. DeRoover, C. Coimbra, L. Weekers, J. Léonet, M. Meurisse, and J.P. Squifflet
Evolution of Native Kidney Function After Pancreas Transplantation Alone H. Le Dinh, A. DeRoover, C. Coimbra, L. Weekers, J. Léonet, M. Meurisse, and J.P. Squifflet ABSTRACT Introduction. This study investigated
Intrahepatic islet transplantation has been demonstrated
Intrahepatic Islet Transplantation in Type 1 Diabetic Patients Does Not Restore Hypoglycemic Hormonal Counterregulation or Symptom Recognition After Insulin Independence Breay W. Paty, 1,2 Edmond A. Ryan,
Islet Transplantation
Islet Transplantation Policy Number: Original Effective Date: MM.07.027 07/01/2014 Line(s) of Business: Current Effective Date: HMO; PPO 3/24/2017 Section: Transplants Place(s) of Service: Inpatient I.
Pancreas/kidney transplant outcome functioning renal transplants (4). A small number of centers in the United States have also embarked upon living re
Hong Kong Journal Nephrol of 1999;1(1):11-17. Nephrology 1999;1(1):11-17. R E V I E W A T R I C L E Simultaneous pancreas and kidney transplantation: a review of outcome from a single center Jeremy R CHAPMAN,
In-situ v Normothermic Regional Perfusion for Abdominal Organs
In-situ v Normothermic Regional Perfusion for Abdominal Organs ANGEL RUIZ M.D. DONATION AND TRANSPLNAT COORDINATION UNIT MEDICAL DIRECTION HOSPITAL CLÍNIC DE BARCELONA Introduction Donation after circulatory
Manchester Royal Infirmary Renal & Pancreas Transplant Unit / 2011 Activity Annual Report
Manchester Royal Infirmary Renal & Pancreas Transplant Unit 21 / 211 Activity Annual Report Vicki Bowman Renal Transplant Audit & Data Manager Dr Susan Martin Consultant Clinical Scientist / Transplantation
Treatment Induced Neuropathy of Diabetes. Christopher Gibbons MD, MMSc
Treatment Induced Neuropathy of Diabetes Christopher Gibbons MD, MMSc Background 1. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Annals of neurology
ICD-10-AM/ACHI/ACS Eighth Edition. HIMAA/NCCH Conference Renal workshop October 2014
ICD-10-AM/ACHI/ACS Eighth Edition HIMAA/NCCH Conference Renal workshop October 2014 Record 1 N18.5 Chronic kidney disease, stage 5 E11.22 Type 2 diabetes mellitus with established diabetic nephropathy
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
Public Statement: Medical Policy Statement: Medical Policy Title: Transplant, Allogeneic, Islet Cell or Pancreas for Diabetes Mellitus
ARBenefits Approval: 02/08/2012 Effective Date: 01/01/2013 Revision Date: 01/15/2014 Medical Policy Title: Transplant, Allogeneic, Islet Cell or Pancreas for Diabetes Mellitus Document: ARB0387:02 Administered
β-cell Preservation and Regeneration After Islet Transplantation
β-cell Preservation and Regeneration After Islet Transplantation Jyuhn-Huarng Juang, MD Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung University and Memorial Hospital,
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
Pathways to Protecting from Autoimmunity the Resurrected/Regenerated Beta Cells. Jeffrey Bluestone, PhD Diabetes Center at UCSF
Pathways to Protecting from Autoimmunity the Resurrected/Regenerated Beta Cells Jeffrey Bluestone, PhD Diabetes Center at UCSF Number of Transplants Is islet replacement a viable option? 2000 1800 1600
Simple Measures to Monitor b -Cell Mass and Assess Islet Graft Dysfunction
American Journal of Transplantation 2007; 7: 303 308 Blackwell Munksgaard C 2006 The Authors Journal compilation C 2006 The American Society of Transplantation and the American Society of Transplant Surgeons
Definitions. You & Your New Transplant ` 38
Definitions Acute Short, relatively severe Analgesic Pain medicine Anemia A low number of red blood cells Anesthetic Medication that dulls sensation in order to reduce pain Acute Tubular Necrosis (ATN)
Islet Transplantation
Islet Transplantation Policy Number: Original Effective Date: MM.07.027 07/01/2014 Line(s) of Business: Current Effective Date: HMO; PPO 07/01/2014 Section: Transplants Place(s) of Service: Inpatient I.
Islet cell transplantation: current status in the UK
Pratik Choudhary MBBS, MRCP, MD, Senior Lecturer and Consultant in Diabetes, King s College London, London, UK Neil R Parrott MD, FRCS, Consultant Transplant Surgeon, Manchester Royal Infirmary, Manchester,
Impact of graft implantation order on graft survival in simultaneous pancreas kidney transplantation
Transplant International ORIGINAL ARTICLE Impact of graft implantation order on graft survival in simultaneous pancreas kidney transplantation Nadja Niclauss, Beno^ıt Bedat, Philippe Morel, Axel Andres,
PARTICULARS, SCHEDULE 2 THE SERVICES, A SERVICE SPECIFICATION. A03/S(HSS)/a Pancreas transplantation service (Adult)
A03/S(HSS)/a NHS STANDARD CONTRACT FOR PANCREAS TRANSPLANTATION SERVICE (ADULT) PARTICULARS, SCHEDULE 2 THE SERVICES, A SERVICE SPECIFICATION Service Specification No. Service Commissioner Lead Provider
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
Simultaneous islet kidney vs pancreas kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up
Diabetologia (2008) 51:110 119 DOI 10.1007/s00125-007-0860-4 ARTICLE Simultaneous islet kidney vs pancreas kidney transplantation in type 1 diabetes mellitus: a 5 year single centre follow-up P. A. Gerber
What s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
Diabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated
Diabetes mellitus is a complex of syndromes characterized metabolically by hyperglycemia and altered glucose metabolism, and associated pathologically with specific microvascular and macrovascular complications.
Using the cost effectiveness of allogeneic islet transplantation to inform induced pluripotent stem cell-derived β-cell therapy reimbursement
For reprint orders, please contact: reprints@futuremedicine.com Using the cost effectiveness of allogeneic islet transplantation to inform induced pluripotent stem cell-derived β-cell therapy reimbursement